Home Blog Page 630

Lunit to Be Featured in 21 AI Imaging Studies on Breast Cancer and Lung Disease at ECR 2026

  • 13 oral presentations included, reaffirming the clinical value of AI-based medical image analysis
  • Highlighting key topics such as early risk stratification based on AI abnormality scores and interval cancer classification

SEOUL, South Korea, March 4, 2026 /PRNewswire/ — Lunit (KRX:32813), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 21 studies featuring its AI solutions will be presented at the European Congress of Radiology 2026 (ECR 2026), taking place March 4-8 in Vienna, Austria.

At this year’s congress, independent studies evaluating the clinical value of Lunit INSIGHT MMG, Scorecard, and Lunit INSIGHT CXR will be presented. Of the 21 accepted abstracts, 13 have been selected for oral presentations, which represent the congress’s main scientific sessions, while eight will be presented as posters.

One of the key studies featuring Lunit’s solutions to be presented at ECR 2026 is an early breast cancer risk assessment study conducted by Dr. Claudia Weiss and her team at AULSS n.2 “Marca Trevigiana”, a regional health authority in Treviso, Italy.

The researchers analyzed mammography data from 67,686 women to evaluate whether a risk score derived using Lunit INSIGHT MMG could identify women who were initially assessed as normal but were at higher risk of a subsequent breast cancer diagnosis.

The analysis showed that among 451 women who were ultimately diagnosed with breast cancer, the average score rose sharply from 15.4 at the first screening to 73.9 at the second screening. In contrast, among 67,235 women who were assessed as negative at both screenings, the average score showed little change, decreasing slightly from 6.7 to 6.4. This difference was observed regardless of breast density, demonstrating the potential of using Lunit INSIGHT MMG as a tool for early identification of women at high risk of developing breast cancer.

A study examining the potential role of AI in the interval cancer audit process will also be presented. A research team led by Professor Yan Chen at the University of Nottingham evaluated the applicability of AI in the interval cancer classification process of the UK’s NHS Breast Screening Programme (NHSBSP). Currently, within the NHSBSP, two expert readers retrospectively review interval cancer cases and classify them into Category 1, 2, or 3[1].

The researchers applied Lunit INSIGHT MMG to 409 interval cancer cases and assessed whether AI scores could distinguish Category 1 cases from Category 2 and 3 cases. Using a predefined approach in which cases with AI scores below a given threshold were classified as Category 1 and those above the threshold as Category 2 or 3, the AI correctly classified 63 of 65 cases as Category 1 at a threshold of 0.5, and 206 of 229 cases at a threshold of 10. Notably, under both thresholds, no Category 3 cases were incorrectly classified as Category 1. These results suggest that AI could be used as a supportive tool to prioritize Category 1 cases, which account for the majority of interval cancers, and to help specialists focus on cases requiring more detailed evaluation.

The results of a large-scale randomized controlled trial (RCT) using the breast density quantification solution Scorecard from Lunit International (formerly Volpara) will also be presented. A research team led by Dr. Carla van Gils at UMC Utrecht followed women who had negative mammography results but were classified as having extremely dense breasts by Scorecard, to assess whether supplemental MRI screening could reduce the incidence of advanced breast cancer.

The researchers followed 8,061 women in the MRI screening group and 32,312 women in the control group who received mammography only across three screening rounds. At the third screening round, the incidence of advanced breast cancer in the MRI group was statistically significantly lower than in the control group, by 2.6 cases per 1,000 women. This study suggests that strategies to more precisely screen women with extremely dense breasts through identification with quantitative density assessment offered by Scorecard, and to link them with appropriate additional screening, may lead to real clinical benefits.

“These studies demonstrate that AI can contribute beyond simple reading support, extending to early risk assessment, screening quality management, and identification of high-risk populations.” said Brandon Suh, CEO of Lunit. “We will continue to build clinical evidence that can be applied in real-world global screening environments through ongoing collaboration with leading medical institutions around the world.”

ECR is one of Europe’s leading radiology congresses and is widely recognized as a major international medical imaging conference. Held under the theme of “Rays of Knowledge”, ECR 2026 is expected to bring more than 20,000 radiologists, researchers, and industry professionals from around the world. Lunit has participated in ECR every year since 2020, consistently presenting its research and clinical results.

Join Lunit at booth AI-10 in the hall Expo X1 to discover how our clinically validated AI solutions support radiologists in daily practice.

ECR 2026 Lunit Abstract Information

No.

Session
Number #

Session Title

Session Type

1

RPS 1402

External Validation of Four Breast Cancer Risk Models With and Without Breast Density in a prospective Dutch Screening Cohort

Oral

Presentation

2

RPS 1402

AI-assisted double reading in mammography screening: exam risk score patterns and early cancer risk prediction

Oral

Presentation

3

RPS 1002

Supplemental MRI screening for women with extremely dense breasts: results of three screening rounds of the DENSE trial

Oral

Presentation

4

RPS 1905

AI performance on an interval cancer mammography dataset and its role in audit triage

Oral

Presentation

5

RPS 1905

Comparing the Performance of Top Ranked AI Models from the RSNA 2023 Screening Mammography Breast Cancer Detection AI Challenge to Commercial AI Models

Oral 

Presentation

6

RPS 1102

Empirically determined effect of dataset size and enrichment on threshold selection of a commercial mammography AI algorithm

Oral

Presentation

7

RPS 1102

Artificial intelligence–assisted risk stratification of atypical breast lesions: correlation of pathology, imaging features and Lunit abnormality score

Oral

Presentation

8

RPS 1102

AI-only for assessing breast cancer screening mammograms – the evolution with AI as an independent reader

Oral

Presentation

9

RPS 1102

Artificial intelligence reveals early mammographic signs of breast cancers diagnosed at subsequent screening

Oral

Presentation

10

RPS 1105

Is Digital Breast Tomosynthesis (DBT)-based Artificial Intelligence (AI) Better than 2D Mammography-based AI?

Oral

Presentation

11

RPS 1905

Large-scale AI implementation in Radiology: technical, operational, and behavioral adoption patterns across a 20-center Swiss Imaging Network

Oral

Presentation

12

RPS 805

Repeated evaluation of AI for lung nodule detection in chest radiographs: version-to-version evaluation in a multicentre study

Oral

Presentation

13

RPS 2102

Diagnostic Accuracy of Contrast-Enhanced Mammography Compared with Breast MRI in Women at Increased Breast Cancer Risk

Oral

Presentation

14

Automated Mammography Breast Positioning Assessment After Surgical Intervention

Poster

15

AI on the Front Line: Real-World Performance of Lunit INSIGHT CXR in a high-volume Tertiary Centre

Poster

16

Evolution of Breast Cancer Screening: From Human-Only Double Reading to AI-Integrated Single Reading – flaggings, recall rates and increased cancer detection rate

Poster

17

Real world monitoring of the threshold for an AI-algorithm in breast cancer screening and different mammography equipments

Poster

18

More Than Hot Air: Enhancing Pneumothorax Detection with AI-Assisted Interpretation

Poster

19

Commercial artificial intelligence tools for chest radiography: diagnostic performance and workflow effects in a prospective crossover

Poster

20

Normal-Flagging for Chest Radiography: pre-clinical evaluation of a dual-engine AI for safe triage and workflow efficiency

Poster

21

Evaluating BI-RADS 4 Mammographic Lesions with Artificial Intelligence: Accuracy and Risk Stratification

Poster

About Lunit

Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis—empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.

Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development. 

Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact—for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io/en.

[1] In the NHS Breast Screening Programme (NHSBSP), interval cancer cases are retrospectively reviewed and classified into three categories: Category 1, difficult to detect at the time of screening; Category 2, potentially detectable in retrospect; and Category 3, visible in retrospect and considered to have been missed.

 

On the Path to $100M: Pigment Launches AI Intent Modeling

The AI-native platform’s new patent-pending Modeler Agent enables enterprises to build and evolve complex planning models at record speed.

As over half of new customers migrate from legacy systems, Pigment continues to redefine enterprise decision-making for the modern era.

PARIS, March 4, 2026 /PRNewswire/ — Pigment, the AI business planning and performance management platform, today announced it is approaching $100 million in annual recurring revenue (ARR), having doubled ARR for the third consecutive year. This momentum reflects a broader industry shift toward AI-first planning platforms built for continuous change. In 2025, 56% of Pigment’s new customers migrated from a legacy vendor to Pigment, as enterprises replaced planning systems that can’t keep up with today’s speed and complexity.

That shift is being accelerated by Pigment’s introduction of intent modeling which is  powered by its new Modeler Agent. This agent is a fundamentally new way to build and evolve planning models and applications, turning an often weeks or months long process into hours or even minutes. Rather than starting with manual, heavy configuration, teams describe the outcome they want and the Modeler Agent translates that intent into governed, production-ready models and applications.

Pigment’s growth is clear market validation that this transition is already underway and accelerating:

  • 56% of new customers have migrated from legacy vendors to Pigment in the past year
  • Pigment’s enterprise customer base grew with leaders like Unilever, Anthropic, Siemens and more choosing Pigment
  • 57% of new revenue now comes from enterprise customers

“Businesses can’t afford to wait weeks or months for models to catch up with reality,” said Eleonore Crespo, co-CEO and co-Founder, Pigment. “The Modeler Agent is a fundamentally different proposition: not a better way to do what legacy planning software has always done, but a complete reimagining of what’s possible. When teams can describe what they need in natural language and have a production-ready model in record speed planning becomes a genuine competitive advantage and the difference between an organization that can keep up with the pace of change and those that get left behind.”

Bringing Intent Modeling to the Enterprise

With intent modeling, Pigment is removing the biggest bottleneck in enterprise planning: the time and specialized expertise required to manually build and update models when the business changes. In legacy systems, even small changes can break models, force reconfiguration, or trigger rebuilds from scratch, slowing decisions, delaying insights, and making planning fragile in the face of constant change.

Now, instead of relying on a technical expert to manually build the structure of a model, write formulas, and check the logic, teams simply describe the outcome they want in natural language. The Modeler Agent translates this into governed, production ready models and applications. Unlike generic AI tools, it’s purpose built for enterprise planning and understands business context: metrics, formulas, data relationships, and governance constraints.

Designed for enterprise safety, the Modeler Agent owns the logic and structure of the applications it generates, enforcing guardrails, automated validation, role-based permissions, and auditable change history so updates follow best practices and won’t inadvertently break existing models.

With the Modeler Agent, business teams can:

  • Build complex planning models and applications from scratch in minutes, using natural language
  • Extend and evolve models continuously by adding new use cases, and updating assumptions as the business changes
  • Ask questions about metrics, formulas and dependencies to understand and document how applications work

The impact is dramatically shorter time to value, a much lower barrier to modeling beyond technical experts, and the ability to model scenarios and use cases teams simply wouldn’t have attempted – or invested the time to build – before. Because models can evolve continuously as the business changes, organizations gain a new level of agility without the reimplementation cycles that slow planning down today.

What starts with planning models can expand into building any business applications in Pigment that require structured logic and governed data. This positions Pigment not only as a planning platform, but as a foundation for enterprise business applications.

“The Modeler Agent has exceeded expectations,” said Jack Silvert, Strategic Finance, Business Systems and Operations, Figma. “What used to take hours of designing, modeling and framework building can now be done in minutes. We can spin up ideas quickly, share them with stakeholders earlier, and iterate faster. It’s like having a sparring partner in your back pocket: you can describe what you want in plain English and it produces Pigment-ready outputs grounded in the context of our business, so we spend our time refining instead of starting from zero.”

“I’ve been excited about the Modeler Agent since I first heard about it, and it’s already proven to be a strong thought partner. I can describe my intent and the agent immediately scopes the work – mapping out data metrics, assumptions, and background calculations – which handles the 25-50% of the upfront structure that usually takes hours to build. I think all model building is going to be agent-assisted here on out.” – Zane Olfert, Strategic Finance Manager, ClickUp.

A New, Unified AI Experience

The Modeler Agent is part of a reinvented Pigment AI experience that brings all agents into a single place in the platform, making planning and analysis more intuitive and accessible for customers.

This unified experience includes an upgraded Analyst Agent that now operates in conversational mode, and has enhanced capabilities such as code execution, which enables users to explore data, refine analysis, and generate reports through progressive conversation. Analysts can convert validated conversations into automated Missions, transforming exploratory analysis into recurring, governed workflows. This replaces rigid, upfront prompt writing with an iterative path from exploration to automation.

Pigment is also introducing Custom Agents, allowing organizations to configure AI agents around their specific processes, terminology, and internal knowledge. Teams can define how agents behave, what knowledge they use, and which capabilities they can access, ensuring AI reflects how each organization works while remaining fully aligned with Pigment’s governance and permission model.

The Engine Powering Enterprise AI

Intent modeling and Pigment’s agentic capabilities are only possible because of Pigment’s patent-pending engine designed specifically for enterprise AI. Unlike legacy architectures where intelligence is retrofitted onto outdated systems, Pigment’s engine provides the foundation AI requires to operate at scale:

  • Unified, governed data and shared business context, so agents and humans operate on the same definitions, permissions, and understanding across the entire organization
  • Real-time dynamic modeling so structure and logic can evolve continuously, enabling the Modeler Agent to build and refine models as the business grows and conditions change
  • Elastic scale to handle dynamic AI workloads for consistent performance

Learn more about Pigment’s Modeler Agent here.

About Pigment

Pigment is an AI business planning and performance management platform. Built for the complexity of modern enterprises, Pigment combines dynamic modeling with autonomous AI agents and an intuitive UX, to help teams make intelligent decisions with speed and clarity. Across finance, sales, supply chain, and other business functions, teams at companies like Unilever, Snowflake, Siemens, and Anthropic use Pigment every day to anticipate change, plan ahead, and act with confidence.

Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)

  • Collaboration will evaluate Akeso’s cadonilimab in combination with INOVIO’s INO-5412 (INO-5401 plus INO-9012) as a potential treatment for glioblastoma (GBM), the most common and aggressive form of brain cancer
  • Novel combination therapy will be studied as part of the Phase II adaptive platform trial known as the INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT), sponsored by the Dana-Farber Cancer Institute
  • Study builds on the previously reported positive Phase II results involving INO-5401 in GBM, adding a novel, first-in-class PD-1/CTLA-4 bi-specific immunotherapy, which potentially provides additional checkpoint inhibition through CTLA-4 binding.

HONG KONG and PLYMOUTH MEETING, Pa., March 4, 2026 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso”), and INOVIO (NASDAQ: INO) today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate cadonilimab, Akeso’s first-in-class PD-1/CTLA-4 bispecific antibody, in combination with INO-5412, INOVIO’s DNA immunotherapy candidate, for the potential treatment of GBM. The combination therapy will be studied as a part of INSIGhT, the innovative Phase II adaptive platform trial sponsored by the Dana-Farber Cancer Institute and conducted with Mass General Brigham Cancer Care, Inc., which is designed to quickly and efficiently find new treatments for GBM. Dosing in the combination therapy trial is expected to begin in the second half of 2026.

Cadonilimab has received marketing approval in China for several indications, including first-line gastric cancer, first-line cervical cancer, and second/third-line cervical cancer, demonstrating effectiveness irrespective of PD-L1 expression status. As the world’s first approved bispecific antibody for cancer immunotherapy, cadonilimab has established its clinical value through real-world application and validation across multiple Phase III trials. The drug is currently involved in over 11 Phase III/registration clinical studies including global programs such as a Phase III registrational trial for the first-line treatment of gastric cancer, and a Phase II registrational trial for the second-line treatment of liver cancer in patients who exhibit resistance to immune checkpoint inhibitors (IO).

INO-5412 is composed of INO-5401 and T cell immune activator INO-9012. When combined with a checkpoint blockade, targeted DNA immunotherapy has the potential to overcome the challenges of immune checkpoint therapy alone by stimulating an immune response against tumor antigens and driving T cell infiltration into the glioblastoma tumor microenvironment. In an ongoing Phase II trial in newly diagnosed GBM patients, INO-5401 plus INO-9012 in combination with a PD-1 checkpoint inhibitor elicited robust immune responses that potentially correlate with enhanced survival. The novel combination of INO-5412 with cadonilimab to treat GBM builds on this promising data and could potentially benefit patients by providing additional checkpoint inhibition through CTLA-4 binding.

Dr. David Reardon, Director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute and a professor at Harvard Medical School said, “The INSIGhT trial was designed to help quickly advance cutting-edge treatments for GBM, the most common and aggressive form of brain cancer for which there are few effective treatments currently available or in development. We are excited to include INOVIO and Akeso’s novel combination immunotherapy in the trial and welcome their efforts to help improve potential outcomes for patients.”

Yu (Michelle) Xia, PhD, founder, chairwoman, president, and Chief Executive Officer of Akeso, said, “We are truly excited to collaborate with INOVIO for the treatment of GBM. We are advancing cadonilimab worldwide through Akeso’s ‘in-house innovation + global partnership’ strategy to realize its breakthrough clinical benefits for patients all around the world across multiple cancer types. By collaborating with INOVIO, we aim to harness the benefit of combining INOVIO’s DNA medicine with cadonilimab’s dual checkpoint inhibition for the treatment of GBM, a particularly challenging central nervous system malignancy. We also look forward to working with one of the world’s leading cancer centers in the clinical development of the new cadonilimab and INO-5412 combination treatment for GBM.”

Dr. Michael Sumner, INOVIO’s Chief Medical Officer, said, “This collaboration is an important step forward for our cancer immunotherapy research and we are delighted to partner with two trailblazing organizations to advance this promising candidate in our late-stage clinical pipeline. Combining INO-5412 with Akeso’s novel checkpoint modality represents an important evolution of our research in GBM, builds on our previous data showing the potential to improve patient outcomes and highlights our ongoing commitment to advancing innovative treatments for diseases with significant unmet need.”

Under the terms of the agreement, INOVIO and Akeso will provide support for the INSIGhT study, including supplying their respective therapeutic products, while the investigative sponsors will oversee the day-to-day clinical operations.

About Cadonilimab
Cadonilimab, independently developed by Akeso, is the world’s first PD-1/CTLA-4 bispecific immuno-oncology therapy. It has been approved and reimbursed in China for three indications: recurrent/metastatic cervical cancer after platinum-based chemotherapy failure, first-line gastric cancer, and first-line cervical cancer. The drug has also been investigated in over 30 clinical trials spanning more than 20 tumor types. Currently, 11 Phase III or registrational trials are ongoing, with three already having met primary endpoints. With a novel dual-targeting mechanism against PD-1 and CTLA-4, cadonilimab demonstrates superior efficacy and a favorable safety profile compared to combination therapies. It has shown strong anti-tumor activity regardless of PD-L1 status and holds breakthrough potential in IO-resistant and immunologically “cold” tumors.

About INO-5412
INO-5412 is an investigational DNA medicine that combines INO-5401 and INO-9012 into a single vial as a potentially powerful cancer immunotherapy particularly when given in combination with checkpoint inhibitors. INO-5401 plus INO-9012 has been previously investigated as a potential therapeutic treatment targeting a number of cancers, including GBM and cancers exhibiting BRCA1 and BRCA2 mutations. Data from an ongoing Phase II trial in newly diagnosed GBM patients, highlighted in a 2022 oral presentation at the American Society of Clinical Oncology (ASCO), demonstrated that INO-5401 plus INO-9012 in combination with a PD-1 checkpoint inhibitor elicited robust immune responses that potentially correlated with enhanced survival. (Reardon D. et al, ASCO 2022).

INO-5401 encodes for INOVIO’s SynCon® antigens for hTERT, WT1, and PSMA, which are antigens The National Cancer Institute has highlighted as important targets and designated as high priorities for cancer immunotherapy development. These three antigens have been reported to be over-expressed and often mutated in a variety of human cancers, including GBM. INO-9012 encodes for IL-12, which is a T cell immune activator. 

About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its proprietary Tetrabody bispecific antibody platform, ADC (Antibody-Drug Conjugate) technologies, siRNA/mRNA modalities, and cell therapies. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has evolved into a globally competitive biopharmaceutical focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 26 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO’s technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

About INOVIO’s DNA Medicines Platform
INOVIO’s DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO’s proprietary investigational medical device, CELLECTRA. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that work like software the body’s cells can download to produce specific proteins to target and fight disease. INOVIO’s proprietary CELLECTRA delivery devices are designed to optimally deliver its DNA medicines to the body’s cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.

Akeso Forward-Looking Statements
This announcement by Akeso, Inc. (9926.HK, “Akeso”) contains “forward-looking statements”. These statements reflect the current beliefs and expectations of Akeso’s management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso’s other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

INOVIO Forward-Looking Statements
This press release contains certain forward-looking statements relating to our business, including INOVIO’s planned clinical collaboration with Akeso to advance novel combination therapy for GBM, plans for the combination therapy to be studied as part of INSIGhT, the expected timing for dosing in the combination therapy trial to begin in the second half of 2026, as well as the potential benefits of INO-5412 in combination with a checkpoint inhibitor such as cadonilimab. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured, or commercialized, that the results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.

 

 

OPPO and MediaTek Showcase On-Device AI Innovations at MWC 2026


BARCELONA, SPAIN – Media OutReach Newswire – 4 March 2026 – OPPO and MediaTek showcased new on-device AI advancements at MediaTek’s “AI for Life” keynote during Mobile World Congress (MWC) 2026. Jason Liao, President of the OPPO Research Institute, highlighted how deep collaboration between the two companies is accelerating AI deployment on smartphones.

Jason Liao Speaking at MediaTek Keynote
Jason Liao Speaking at MediaTek Keynote

The event marked the rollout of new on-device AI capabilities, progress on the jointly developed Omni Model, and advances in cross-ecosystem connectivity — outlining a shared vision for the next generation of AI Phones.

From Chip to Experience: Advancing On-Device AI

As mobile experiences become increasingly AI-driven, OPPO is advancing its AI strategy centered on “New Computing, New Perception, and New Ecosystem.” At the core of this strategy is “On-device Compute”, enabling low-latency, privacy-preserving, and personalized AI experiences. As Jason Liao emphasized, “On-device Compute is a cornerstone of OPPO’s AI strategy, making AI a perceptible, real-time experience integrated into everyday usage.” This shared vision underpins the deep collaboration between OPPO and MediaTek on flagship chip platforms, accelerating the transition of on-device AI from technical concept to scalable deployment.

Powered by the MediaTek Dimensity 9500 platform, OPPO’s self-developed on-device AI Translate and AI Portrait Glow now deliver performance comparable to cloud-based solutions. These features will soon roll out to OPPO Find X9 Series through the upcoming ColorOS 16 software update.

The on-device AI Translate can run directly on the device, achieving an average 15% improvement in accuracy over conventional approaches while supporting seamless multilingual translation. It maintains stable output even without internet connectivity or under weak signal conditions, enabling reliable translation across diverse scenarios.

Meanwhile, on-device AI Portrait Glow enhances portraits captured in challenging lighting environments. By intelligently analyzing and reconstructing scene illumination, it improves results in dim or backlit conditions while maintaining natural rendering — all without network reliance. Demonstrations have showcased exceptional performance in both visual realism and adaptability to various scenes.

OPPO On-device AI Features
OPPO On-device AI Features

OPPO and MediaTek also unveiled a technology preview of Omni, the industry’s first on-device full-modal AI model designed for multi-modal understanding and interaction. Supporting voice, video, and text inputs, Omni enables live scene understanding and interactive Q&A directly on a smartphone. This advancement strengthens on-device AI’s ability to perceive and interpret the physical world, laying the foundation for more proactive and natural human–computer interaction.

OPPO On-device Omni Model
OPPO On-device Omni Model

Demonstrating Ecosystem Integration and Innovation

The collaboration was further showcased in the interactive experience zone at the MediaTek booth, where attendees explored Find X9 Pro’s on-device AI capabilities alongside its telephoto imaging with the OPPO Hasselblad Teleconverter. Reno15 Pro was also featured, presenting creative AI imaging tools including AI Motion Photo Eraser, AI Motion Photo Popout, and the AI Flash Photography.

OPPO at MediaTek Booth
OPPO at MediaTek Booth

Coming soon, OPPO’s Find X9 Series will bring Android™ Quick Share, enabled in close collaboration with MediaTek and Google. Without installing third-party applications, users can conveniently and securely transfer files between OPPO smartphones and iOS, iPadOS and macOS devices, improving cross-platform interoperability. The feature is expected to begin rolling out via software update starting in March.

At MWC 2026, OPPO Find X9 Pro was shortlisted for the “Best Smartphone” award at the GLOMO Awards, gaining recognition for its innovation across performance, imaging, and AI integration.

Looking ahead, OPPO and MediaTek will continue strengthening collaboration in frontier areas such as on-device AI to advance user experience. Together, the two companies remain committed to delivering more powerful and reliable AI experiences to users worldwide.

* Google, Android and Quick Share are trademarks of Google LLC.

Hashtag: #OPPO

The issuer is solely responsible for the content of this announcement.

About OPPO

OPPO is a leading global smart device brand. Since the launch of its first mobile phone – “Smiley Face” – in 2008, OPPO has been in relentless pursuit of the perfect synergy of aesthetic satisfaction and innovative technology. Today, OPPO provides a wide range of smart devices spearheaded by the Find and Reno series. Beyond devices, OPPO also provides its users with ColorOS operating system and internet services. OPPO has footprints in more than 70 countries and regions, with more than 40,000 employees dedicated to creating a better life for customers around the world.

MEXC Partners with Ondo Finance to Launch Tokenized US Equities in Defense and Energy Sectors

VICTORIA, Seychelles, March 4, 2026 /PRNewswire/ — MEXC, the fastest-growing global cryptocurrency exchange, redefining a user-first approach to digital assets through true zero-fee trading, today announced the launch of seven tokenized US equities across defense and energy sectors in partnership with Ondo Finance. The tokens are available for immediate trading on MEXC.

MEXC Partners with Ondo Finance to Launch Tokenized US Equities in Defense and Energy Sectors
MEXC Partners with Ondo Finance to Launch Tokenized US Equities in Defense and Energy Sectors

The assets trade as ERC-20 smart contracts against USDT pairs, with two separate launch tranches at 12:00 UTC and 13:00 UTC on March 4, 2026, and withdrawals beginning March 5, 2026. Each token represents direct ownership of the underlying US equity, with holdings verified through quarterly third-party audits and held in regulated trust accounts. The offering includes LMTON/USDT, RTXON/USDT, BBAION/USDT, ACHRON/USDT, COPON/USDT, OXYON/USDT, and ONDSON/USDT.

Tokenized equities provide continuous trading access across geographies while removing position minimums and qualified investor restrictions. Defense and energy stocks have historically traded with wide bid-ask spreads and limited retail accessibility. This launch expands institutional-grade market access to MEXC’s 15+ million users.

MEXC remains committed to delivering institutional-quality assets and infrastructure to the global retail and professional trading community. Full product details and real-time trading data available here.

About MEXC

Founded in 2018, MEXC is committed to being “Your Easiest Way to Crypto.” Serving over 40 million users across 170+ countries, MEXC is known for its broad selection of trending tokens, everyday airdrop opportunities, and low trading fees. Our user-friendly platform is designed to support both new traders and experienced investors, offering secure and efficient access to digital assets. MEXC prioritizes simplicity and innovation, making crypto trading more accessible and rewarding.
MEXC Official Website X  Telegram How to Sign Up on MEXC

Beetles Gel Polish Brings Experiential Beauty to New York with “Taste of Spring” Immersive Activation

A thoughtfully designed pop-up experience welcomes spring to New York through color, creativity, and community.

NEW YORK, March 4, 2026 /PRNewswire/ — On March 3, Beetles Gel Polish transformed New York City into a celebration of spring with its Spring 2026 “Taste of Spring” immersive activation at Maison Welles. With effortless execution and an atmosphere brimming with seasonal charm, the event beautifully showcased the brand’s continued expansion of community-driven experiences across the US.

Beetles Taste of Spring Afternoon Tea
Beetles Taste of Spring Afternoon Tea

A Spring Story Told Through Nails

Centered around the uplifting theme “Get a Taste of Spring. Refresh the Year Ahead.” the activation brought the collection’s seasonal color story to life in the most delightful way. Rather than a traditional retail pop-up, guests stepped into a carefully curated, multi-sensory escape—where hands-on gel manicure stations met a dessert-inspired afternoon tea setting. The result was more than a product showcase; it was a vibrant lifestyle moment that seamlessly connected innovation, creativity, and feel-good spring energy.

An Immersive Spring Nail Gathering

Inspired by the first blush of early spring, the “Taste of Spring” palette delighted guests with airy pastels and soft jelly finishes that felt as fresh as the season itself. The all-in-one Taste of Spring Gel Box—packaged in an irresistibly charming candy-house–shaped design—offered an approachable at-home manicure solution for both beginners and seasoned nail lovers.

Beetles Taste of Spring Afternoon Tea
Beetles Taste of Spring Afternoon Tea

In collaboration with Maison Welles, beauty met culinary artistry through a thoughtfully crafted seasonal drinks and dessert menu designed to echo the collection’s color story. From the space design to the product displays and coordinated limited menu, every touchpoint reflected a cohesive and elevated creative direction. The seamless integration of aesthetics and experience spoke volumes about Beetles Gel Polish’s expertise in experience-led engagement.

Connecting with the City

Though March 3 was cold and rainy in New York, stepping into Beetles Gel Polish’s activation felt like walking straight into spring. The vibrant, thoughtfully curated space brought warmth and brightness to the city—and to every guest who attended.

Despite the drizzle, many New Yorkers who spotted the event on local activity pages came out with umbrellas in hand, lining up lively to join the experience—proof that even rainy weather couldn’t dim the excitement surrounding “Taste of Spring.”

The “Taste of Spring” collection will remain on display at Maison Welles through March 15, giving visitors continued opportunities to explore the collection and participate in seasonal giveaway activities tied to the launch.

Expanding an Experiential Vision

As demand for at-home gel manicure solutions continues to rise across the world, Beetles Gel Polish is leaning confidently into experiential initiatives that make accessibility feel inspiring and joyful. The New York activation highlights the brand’s strategic investment in immersive marketing across key urban markets—delivering not just products, but memorable moments.

The Taste of Spring collection is currently available on the Beetles Gel Polish official website and Amazon, alongside additional pastel-forward and seasonally inspired gel sets perfect for welcoming the months ahead.

About Beetles Gel Polish

Founded in the U.S. in 2017, Beetles Gel Polish has grown into a leading DIY nail beauty brand, celebrated for its salon-grade formulas and trend-driven color collections. With a strong digital retail presence and thoughtfully executed experiential activations, the brand is expanding into more brick-and-mortar retail channels across the U.S.—making it easier than ever for shoppers to find Beetles Gel Polish at nearby Walmart and Target locations, and bring creativity, confidence, and a touch of color to everyday beauty rituals.

Read more about Beetles Gel Polish at: https://www.beetlesgel.com/pages/blogs

Press Contact
Beetles Gel Polish PR Team
brand@beetlesgel.com

Cellebrite Files its 2025 Annual Report on Form 20-F

TYSONS CORNER, Va. and PETAH TIKVA, Israel, March 4, 2026 /PRNewswire/ — Cellebrite (Nasdaq: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced that the Company has filed its Annual Report on Form 20-F for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the “SEC”).

Cellebrite’s 2025 Annual Report on Form 20-F is available on the investor relations section of its website at https://investors.cellebrite.com/financial-information/sec-filings and on the SEC’s website at www.sec.gov. Shareholders may request a hard copy of the 2025 Annual Report on Form 20-F, free of charge, by contacting the Company at investors@cellebrite.com.

References to Websites and Social Media Platforms
References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

About Cellebrite
Cellebrite’s (Nasdaq: CLBT) mission is to protect communities, nations and businesses as a global leader in digital investigative and intelligence solutions. More than 7,000 global law enforcement agencies, defense and intelligence organizations and enterprises trust Cellebrite’s AI-powered software portfolio to make forensically sound digital data more accessible and actionable. Cellebrite technology allows customers to accelerate more than 1.5 million legally sanctioned investigations annually, enhance sovereign security, elevate operational efficacy and efficiency and enable advanced mobile research and application security. Available via cloud, on-premises and hybrid deployments, Cellebrite’s technology enables its customers around the globe to advance their missions, elevate public safety and safeguard data privacy. To learn more, visit us at www.cellebrite.com.

Investor Relations
Andrew Kramer
Vice President, Investor Relations
investors@cellebrite.com
+1 973.206.7760

Media
Victor Cooper
Sr. Director of Corporate Communications + Content Operations
Victor.cooper@cellebrite.com
+1 404.804.5910

“Study in Hong Kong” Week spotlights city’s competitive higher education sector


HONG KONG SAR – Media OutReach Newswire – 4 March 2026 – The inaugural “Study in Hong Kong” Week (February 23 to March 1) was successfully launched to promote the city’s attractiveness as a destination for students around the world to pursue higher education.

A major highlight was the prestigious Asia-Pacific Association for International Education (APAIE) 2026 Conference and Exhibition, which ranks among the world’s top three international higher education conferences. The event attracted over 3,500 leading international education professionals to explore the latest trends and critical issues in higher education.

Speaking at the opening ceremony of APAIE 2026, the Hong Kong Special Administrative Region (HKSAR)’s Secretary for Education, Dr Christine Choi said, “To further promote higher education in Hong Kong to the world, we are dedicating this week as the ‘Study in Hong Kong’ Week, during which we will share our success stories and connect more closely with partners worldwide.”

HKSAR's Secretary for Education, Dr Christine Choi (second row, ninth left), visits the
HKSAR’s Secretary for Education, Dr Christine Choi (second row, ninth left), visits the “Study in Hong Kong” Pavilion at the APAIE with other guests

“Under the “one country, two systems” principle, Hong Kong enjoys the distinctive advantages of being part of China with strong support from our Motherland and at the same time being centrally located in Asia.

“Our universities are globally recognised, with five of them within the world’s top 100 and Asia’s top 20. Hong Kong claimed all top four spots in the ranking of the world’s most international universities last year. Indeed, one in every four of our students come from outside Hong Kong. The proportion is even higher for academic staff, with around 70 per cent from elsewhere.”

Held under the theme “Asia-Pacific Partnerships for the Global Good”, APAIE 2026 featured pre-conference workshops, summit forums, keynote speeches, and exchange activities.

Dr Choi met with education officials and representatives from various regions on international education development trends and co-operation. She held separate meetings with the State Secretary of the Ministry of Education, Research, Development and Youth of the Slovak Republic, Mr Róbert Zsembera, and the Director General of the International Cooperation Department of the Ministry of Education and Training of Vietnam, Dr Nguyen Thu Thuy, to exchange views on the development, co-operation, and promotion of international higher education.

Dr Choi also toured the “Study in Hong Kong” Pavilion, where she learned about the promotional efforts of University Grants Committee (UGC)-funded universities and how they expand international networks to recruit students from various regions for study and exchange in Hong Kong. She also visited other booths at the exhibition, exchanging views on higher education development with representatives from various countries and regions.

Dr Choi noted that Hong Kong, as Asia’s world city, possesses advantages in global connectivity, world-class infrastructure, and rich cultural experiences that attract outstanding talent.

During the Week, UGC-funded universities hosted campus tours, allowing overseas guests to experience first-hand the fusion of diverse cultures from different regions. Universities also organised student exchange activities to foster friendships among international students from different regions, deepen their understanding of Hong Kong, and help them better integrate into local campus life.

“While Hong Kong is highly popular among students from the Chinese Mainland, those from other parts of the world, especially in the Association of Southeast Asian Nations (ASEAN) and Belt and Road countries or regions, have increased significantly in recent years,” Dr Choi said.

“As we welcome more non-local students to our schools and universities, we hope Hong Kong can serve as a springboard for them to engage with the Chinese Mainland and the wider Asia-Pacific, and as a pathway to widen collaborations across this vibrant region.”

Hashtag: #hongkong #brandhongkong #asiasworldcity #StudyinHongKong #Asia-PacificAssociationforInternationalEducation #APAIE





The issuer is solely responsible for the content of this announcement.